Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mentor silicone submission

This article was originally published in The Gray Sheet

Executive Summary

Mentor has filed a PMA for its Contour Profile silicone gel breast implants, firm announces April 3. The Contour implants are filled with the same Memory Gel for which Mentor received an "approvable" letter for round implants from FDA last summer. Competitor Allergan/Inamed's silicone gel breast implants also sit on a September "approvable" letter. Though neither company will speculate, analysts project FDA approval of both firms' products as early as June 2006 (1"The Gray Sheet" April 3, 2006, p. 6). Furthering its shift to aesthetics, Mentor signed an agreement with Niadyne Inc. on March 20 to distribute Niadyne's NIA 24 skin therapy products...

You may also be interested in...



Allergan Details Revenue Expectations From Newly Acquired Inamed

Allergan expects its recently completed acquisition of Inamed to add $355 mil. to $395 mil. in sales revenue this year

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel